VIVO 外匯新聞
Meridian Bioscience Gets FDA Re-authorization Of EUA For Revogene SARS-CoV-2 Molecular Assay
Diagnostic testing provider Meridian Bioscience, Inc. (VIVO) announced Friday that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA).
RTTNews
|
895天前
